Solara Clears US FDA Inspection at Puducherry Plant With VAI Status

Solara Active Pharma Sciences has successfully cleared a US FDA inspection at its Puducherry manufacturing plant, earning a Voluntary Action Indicated (VAI) status and reinforcing its compliance with global pharmaceutical quality standards. The regulatory clearance is seen as an important milestone for the company, especially as it continues to strengthen its presence in regulated international markets.

The inspection was carried out at Solara’s Puducherry facility, which manufactures ibuprofen manufacturing products and related pharmaceutical ingredients, between February 2 and February 6, 2026. After reviewing the plant’s operations, the United States Food and Drug Administration issued an Establishment Inspection Report (EIR), officially closing the inspection process.

During the inspection, the US FDA made four observations under Form FDA 483. These observations were procedural in nature and did not lead to any regulatory action. Solara stated that it addressed the observations within the required timeline and worked closely with the agency to ensure compliance.

Also Read: Delhi Expands Homoeopathy Push Through AYUSH Integration Drive

A VAI classification means the regulator identified certain issues that required attention, but they were not serious enough to affect product quality, halt production, or restrict exports. This status allows the company to continue supplying products to international markets without disruption.

The Puducherry plant plays an important role in Solara’s manufacturing network and supports both domestic and export demand. The facility has previously undergone reviews by several global regulators, including the US FDA and European health authorities, reflecting its importance in serving regulated pharmaceutical markets.

Industry experts note that positive inspection outcomes are critical for pharmaceutical manufacturers because they confirm adherence to current Good Manufacturing Practices (cGMP). Such approvals help companies maintain customer trust and strengthen long-term relationships with global partners.

For Solara, the successful closure of the inspection highlights its continued focus on regulatory compliance, pharmaceutical manufacturing, and operational standards. The development is expected to support the company’s position in the active pharmaceutical ingredients (API) segment, where consistent quality and regulatory approval remain essential for growth.